Abbott Laboratories beat fiscal second-quarter estimates and raised its full-year adjusted diluted EPS guidance to a range of $5.45 to $5.60, up from $5.38 to $5.58, driven by a 42% surge in diagnostics sales to $3.09 billion. Medtronic reported its highest annual revenue growth in ten years, with fiscal 2026 revenue reaching $36.4 billion, up 8.4% as reported, as newer platforms like Symplicity Spyral, now annualizing at approximately $100 million, gained traction. Abbott reaffirmed its full-year comparable sales growth outlook of 6.5% to 7.5%, while Medtronic faces an estimated $250 million tariff headwind in fiscal 2027. Hedge fund ownership of Abbott rose to 73 funds in the first quarter of 2026, while Medtronic's declined to 60.
Abbott LaboratoriesBeat Q2 estimates and raised full-year EPS guidance.
Medtronic PLCStrongest annual revenue growth in a decade, driven by newer platforms.
